Celyad Oncology SA CYAD

$ 0.47 0.0%

Annual report 2022
added 11-23-2024

Celyad Oncology SA Balance Sheet 2011-2024 | CYAD

Annual Balance Sheet Celyad Oncology SA

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-38.1 M	-39.8 M	-22.9 M	-47.6 M	-99.5 M	-27.2 M	-19 M	-585 K	116 K
Long Term Debt	-	-	-	37 K	229 K	326 K	536 K	-	-	-	812 K	-
Long Term Debt Current	137 K	902 K	1.08 M	1.17 M	484 K	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	23.3 M	32.3 M	29.1 M	22.1 M	36.6 M	36.6 M	11.2 M	12.1 M	12.3 M	116 K
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	35.1 M	44.2 M	38.7 M	30.1 M	47.9 M	48.1 M	17.3 M	15.5 M	15.1 M	6.04 M
Deferred Revenue	-	-	2.21 M	346 K	276 K	226 K	1.11 M	898 K	777 K	428 K	-	-
Retained Earnings	-	-	-91.8 M	-74.4 M	-218 M	-180 M	-124 M	-100 M	-71.2 M	-36.4 M	-11.3 M	-9.13 M
Total Assets	19.7 M	79.9 M	66.1 M	89.8 M	94.3 M	77.6 M	139 M	160 M	44 M	32.4 M	13.7 M	6.88 M
Cash and Cash Equivalents	12.4 M	30 M	17.2 M	39.3 M	40.5 M	23.3 M	48.4 M	100 M	-	-	-	-
Book Value	-	79.9 M	31 M	45.6 M	55.6 M	47.5 M	90.9 M	111 M	26.7 M	16.9 M	-1.31 M	840 K
Total Shareholders Equity	-	-	31 M	45.6 M	55.6 M	47.5 M	90.9 M	111 M	-	-	-	-

All numbers in EUR currency

Quarterly Balance Sheet Celyad Oncology SA

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	1.73 M	-	2.1 M	-	2.52 M	-	2.51 M	-	2.97 M	-	3.4 M	-	652 K	-	-	-	3.76 M	-	-	-	3.38 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	22.5 M	-	25.3 M	-	23.3 M	-	34.6 M	-	32.3 M	-	31.5 M	-	29.1 M	-	-	-	22.1 M	-	-	-	36.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-309 M	-	-63.3 M	-	-283 M	-	-91 M	-	-74.4 M	-	-61.5 M	-	-218 M	-	-	-	-180 M	-	-	-	-124 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	79.9 M	-	62.7 M	-	66.1 M	-	75.8 M	-	89.8 M	-	81.4 M	-	94.3 M	-	-	-	77.6 M	-	-	-	139 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	30 M	-	12 M	-	17.2 M	-	26.7 M	-	39.3 M	-	33.7 M	-	40.5 M	-	62.4 M	-	23.3 M	-	-	-	48.4 M	-	-	-	100 M	-	-	-	27.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-	79.9 M	-	62.7 M	-	66.1 M	-	75.8 M	-	89.8 M	-	81.4 M	-	94.3 M	-	-	-	77.6 M	-	-	-	139 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	43.6 M	-	24.9 M	-	31 M	-	30.3 M	-	45.6 M	-	40.9 M	-	55.6 M	-	72.7 M	-	47.5 M	-	-	-	90.9 M	-	-	-	111 M	-	-	-	26.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency